FDA Approves Tislelizumab-jsgr for First-line Treatment of Gastric and Gastroesophageal Junction Cancers

Designing a Safe, Fully Outpatient CAR T-Cell Program in the Community

Nationally, approximately 1 in 5 patients who qualify for CAR T-cell therapy never receive it due to geographic distance, travel burden, or limited availability at specialized inpatient centers. Recognizing a critical need in its community, Mary Bird Perkins Cancer Center in Baton Rouge, Louisiana, launched the region’s first fully outpatient CAR T-cell therapy program for select blood cancers, fundamentally redefining how advanced cellular therapies can be delivered safely outside of a hospital setting and earning the program a 2026 ACCC Innovator Award.